156 related articles for article (PubMed ID: 34085884)
1. Up-to-date role of aflibercept in the treatment of colorectal cancer.
Saoudi Gonzalez N; Salvà F; Ros J; Baraibar I; Marmolejo D; Valdivia A; Cuadra-Urteaga JL; Mulet N; Tabernero J; Élez E
Expert Opin Biol Ther; 2021 Oct; 21(10):1315-1324. PubMed ID: 34085884
[No Abstract] [Full Text] [Related]
2. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
Chau I; Joulain F; Iqbal SU; Bridgewater J
BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI.
Catalano M; Lavacchi D; Giommoni E; Shabani S; Guidolin A; Brugia M; Petrioli R; Ramello M; Pillozzi S; Antonuzzo L; Roviello G
Future Oncol; 2023 Dec; 19(38):2537-2546. PubMed ID: 38050741
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
[TBL] [Abstract][Full Text] [Related]
5. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
6. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
7. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C
Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
Pericay C; Frías C; Abad A; Lamas MJ; Echave M; Oyagüez I; Rubio M; Giménez E; Naoshy S; Joulain F
Farm Hosp; 2014 Jul; 38(4):317-27. PubMed ID: 25137165
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
[TBL] [Abstract][Full Text] [Related]
10. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
Joulain F; Proskorovsky I; Allegra C; Tabernero J; Hoyle M; Iqbal SU; Van Cutsem E
Br J Cancer; 2013 Oct; 109(7):1735-43. PubMed ID: 24045663
[TBL] [Abstract][Full Text] [Related]
11. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
[TBL] [Abstract][Full Text] [Related]
12. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
15. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
16. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
[TBL] [Abstract][Full Text] [Related]
18. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Élez E; Gómez-España MA; Grávalos C; García-Alfonso P; Ortiz-Morales MJ; Losa F; Díaz IA; Graña B; Toledano-Fonseca M; Valladares-Ayerbes M; Polo E; Salgado M; Martínez de Castro E; Safont MJ; Salud A; Ruiz-Casado A; Tabernero J; Riesco MDC; Rodriguez-Ariza A; Aranda E
Br J Cancer; 2022 Apr; 126(6):874-880. PubMed ID: 34937947
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept.
Ciombor KK; Berlin J; Chan E
Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]